

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PuraPharm

PURAPHARM CORPORATION LIMITED

培力農本方有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1498)

**FURTHER UPDATE ON PROPOSED CAPITAL REDUCTION
AND SUBDIVISION OF UNISSUED SHARES
AND
REVISED EXPECTED TIMETABLE**

References are made to (i) the announcement of PuraPharm Corporation Limited (the “**Company**”) dated 1 November 2024; (ii) the circular of the Company dated 5 November 2024 (the “**Circular**”); (iii) the poll results announcement of the extraordinary general meeting of the Company dated 27 November 2024; and (iv) the announcement of the Company dated 27 January 2025 in relation to, among others, the Capital Reduction and the Subdivision. Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

The Board wishes to announce that the hearing of the Company’s petition for the Capital Reduction was held on 27 January 2025 at 9:30 a.m. (Cayman Islands time) before the Court, and on 28 January 2025 (Cayman Islands time), the Court made an order confirming the Capital Reduction. A copy of the order of the Court (the “**Court Order**”) together with the minutes of the EGM (the “**EGM Minutes**”), which approved the Capital Reduction and the Subdivision, are in the process of being filed with the Registrar of Companies in the Cayman Islands. The Capital Reduction and the Subdivision shall become effective upon completion of registration by the Registrar of Companies of the Cayman Islands of the Court Order and the EGM Minutes.

As additional time is required for registration of the Court Order and the EGM Minutes to be completed, set out below is the revised expected timetable for the Capital Reduction and the Subdivision (references below to dates and times are references to Hong Kong dates and times, except as otherwise specified):

Event	Date and time
Registration of court order confirming the Capital Reduction and the minute of the order of the Capital Reduction with the Registrar of Companies in the Cayman Islands	On or before Monday, 24 March 2025 (Cayman Islands time)
Expected time of the Capital Reduction and the Subdivision becoming effective.	before 9:00 a.m. on Monday, 24 March 2025
Expected commencement of dealings in the New Ordinary Shares.	9:00 a.m. on Monday, 24 March 2025
First day of free exchange of existing share certificates for new share certificates for the New Ordinary Shares	Monday, 24 March 2025
Last day of free exchange of existing share certificates for new share certificates for the New Ordinary Shares	Thursday, 24 April 2025

The timetable above is indicative only and may be subject to change. Further announcement(s) will be made by the Company with respect to any subsequent change to the expected timetable above as and when appropriate and in accordance with the Listing Rules.

By order of the Board
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman and Executive Director

Hong Kong, 21 February 2025

As at the date of this announcement, the executive Directors of the Company are Mr. Chan Yu Ling, Abraham and Ms. Man Yee Wai, Viola; the non-executive Director of the Company is Mr. Leung Stephen Kwok Keung; and the independent non-executive Directors of the Company are Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.